RPCI-UPCI Ovarian Cancer SPORE Clinical Trials
Available Clinical Trials
SPORE Project 1
A Phase I/IIb Study of DEC205mAb-NY-ESO-1 Fusion Protein (CDX-1401) Given with Adjuvant Poly-ICLC in Combination with INCB024360 for Patients in Remission with Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma Whose Tumors Express NY-ESO-1 or LAGE-1 Antigen
Upcoming Clinical Trials
- A Phase I/IIa Open Label Clinical Trial Evaluating the Safety and Efficacy of Adoptive Transfer of NY-ESO-1 TCR Engineered Autologous T Cells in Combination with Decitabine in Patients with Recurrent or Treatment Refractory
- A Phase I study of MHC-restricted and MHC-non-restricted targeting of ovarian cancer by αDC1-induced CTLs
View a list of all SPOREs provided by the Translational Research Program at the National Cancer Institute.